Preclinical rat studies have shown neonatal hypoxia-ischaemia as a precursor to diabetes, metabolic syndrome and stroke (Mcpherson et al., 2009), and IGF1 treatment offers neuroprotection after hypoxia-ischaemia (Brywe et al., 2005). This evidence concerns the gene IGF1 and metabolic syndrome.